Clinical Trials

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT02388490 2024-09-23

Bretuximab

25 enrolled 12 charts

Lymphoma, Recurrence

NCT01492088 2024-05-30

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Phase 1/2 Completed

36 enrolled 26 charts

452 enrolled 16 charts 1 FDA

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT01777152 2021-11-30

ECHELON-2

Phase 3 Completed

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT01100502 2021-05-14

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Phase 3 Completed

329 enrolled 15 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT01990534 2021-04-09

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Phase 4 Completed

60 enrolled 21 charts

Hematologic Diseases, Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02243436 2019-04-24

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

67 enrolled

Hodgkin Disease, Lymphoma

NCT01874054 2019-02-12

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Phase 1/2 Completed

55 enrolled 14 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT02567851 2018-05-11

BREVITY

38 enrolled

Hodgkin Disease, Lymphoma

NCT01309789 2017-06-28

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

39 enrolled

Hematologic Diseases, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT00866047 2017-03-22

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

58 enrolled 19 charts

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

NCT01421667 2016-11-28

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

176 enrolled 30 charts

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00079755 2014-12-18

Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma

80 enrolled

Lymphoma, Lymphoma, Large-Cell, Anaplastic

NCT00430846 2014-12-18

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

45 enrolled

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

NCT01026415 2014-12-18

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

73 enrolled

Carcinoma, Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Lymphoma, Large-Cell, Anaplastic

NCT01060904 2014-12-18

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

51 enrolled

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT01026233 2014-12-12

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

52 enrolled